---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-002037"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T01:54:53.089391+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology appoints Fairooz Kabbinavar as Chief Medical Officer

## Summary
- Annual base salary $480,000, target bonus 45% of base, plus option grant.
- Granted non-qualified option for 425,000 shares at $1.75/share exercise price.
- Options vest over 4 years: 25% after 12 months, then monthly over 36 months.
- Dr. Kabbinavar has 30+ years experience; lead investigator for bevacizumab mCRC approval trials.

## SEC filing metadata
- accession: 0001628280-23-002037
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828023002037/0001628280-23-002037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828023002037/crdf-20230202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-002037
- JSON: https://secwatch.observer/filing/0001628280-23-002037.json
- Plain text: https://secwatch.observer/filing/0001628280-23-002037.txt

## Key facts
- Executive change
  Fairooz Kabbinavar was appointed as Chief Medical Officer at Cardiff Oncology, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On January 30, 2023, Cardiff Oncology, Inc. (the “Company”) appointed Dr. Fairooz Kabbinavar as Chief Medical Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828023002037/0001628280-23-002037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.